Clinical Trial Update: Using Hyperpolarized [1-13C]Pyruvate to Detect Cardiotoxicity [EARLY_Phase 1]

View source ↗

Summary

An early-phase Phase 1 trial investigated the use of hyperpolarized [1-13C]pyruvate to detect cardiotoxicity in patients with breast cancer and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Hyperpolarized [1-13C]pyruvate (pyruvate (hyperpolarized with carbon-13))

Snippet

Sponsor: University of Texas Southwestern Medical Center | Conditions: Breast Neoplasms | EARLY_Phase 1 | Status: COMPLETED